Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma

Giornale Italiano di Dermatologia e Venereologia

Volumn 143, Issue 1, 2008, Pages 59-70

  Kalani, A D ^a   Jack, A ^a   Montenegro, G ^a   Degliuomini, J ^a   Wallack, M K ^a,b  

^a METROPOLITAN HOSPITAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

CTLA 4 binding protein, recombinant; Dendritic cells; Immunotherapy; Melanoma, therapy; Polyvalent melanoma cell vaccine; Vaccination

Indexed keywords

CANVAXIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DC MELVAC; DENDRITIC CELL VACCINE; ECOG 1690; ECOG 1694; FLUDARABINE; IPILIMUMAB; MELACINE; MELANOMA VACCINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TICILIMUMAB; UNCLASSIFIED DRUG;

ADOPTIVE CELL TRANSFER; ADVANCED CANCER; AUTOIMMUNE ARTHRITIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL THERAPY; CELL TRANSFER; CHILL; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENTERITIS; EYE TOXICITY; FEVER; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART OUTPUT; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTENSION; LUNG EDEMA; MELANOMA; NONHUMAN; PANCREATITIS; RASH; REVIEW; SIDE EFFECT; TUMOR ASSOCIATED LEUKOCYTE; VASCULAR LEAK SYNDROME; VASCULAR RESISTANCE; VITILIGO;

EID: 42249102069     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Bodenham D. A Study of 650 Observed Malignant Melanoma in the South-West Region. Ann R Coll Surg Engl 1968;43:218-39.
2. Laennec RTH. Sur les Melanoses. Bulletin de la Faculte de Medicine de Paris 1806;1:24-6.
3. Cooper S. First Line of Theory and Practice of Surgery. London: Longman, Orme, Brown, Green, and Longman; 1840.
4. Kadison AS, Morton DL. Immunotherapy of Malignant Melanoma. Surg Clin North Am 2003;83:343-70.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
6. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. J Am Acad Dermatol 2007;57:555-72.
7. st century. J Am Acad Dermatol 1996;34:839-47.
8. Clark WH. Class of Melanoma. London: Pergon Press;1967.
9. Breslow A. Thickness, cross-sectional areas & depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
10. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-49.
11. Greene FL. TNM: Our Language of Cancer. CA Cancer J Clin 2004;54:129-30.
12. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long term survival after lymphadenectomy of melanoma metastatic regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491-9.
13. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-63.
14. Morton DL, Malmfren RA, Holmes EC, Ketcham AS. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968;64:233-40.
15. Mukherji B, Wilhelm SA, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma. Evidence of cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 1986;136:1888-92.
16. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
17. Lee JT, Herlyn M. Microenvironmental influence in melanoma progression. J Cell Biochem 2007;101:862-72.
18. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-Cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001;20:8125-35.
19. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000;36:1607-20.
20. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87:992-1005.
21. Berx G, Becker KF, Höfler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-37.
22. Heasman J, Crawford A, Goldstone K, Garner-Hamrick P, Gumbiner B, McCrea P et al. Overexpression of cadherins and underexpression of beta-catenin inhibit dorsal mesoderm induction in early Xenopus embryos. Cell 1994;79:791-803.
23. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M et al. Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression. Cancer Res 1990;50:6757-64.
24. Valyi-Nagy IT, Hirka G, Jensen PJ, Shih IM, Juhasz I, Herlyn M. Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab Invest 1993;69:152-9.
25. Shih IM, Elder DE, Hsu MY, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 1994;145:837-45.
26. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and Paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-54.
27. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor, and cancer research: a historical perspective. Pharmacol Ther 1994;64:529-64.
28. Halpern BN, Biozzi G, Stiffel C, Mouton D. Inhibition of tumor growth by administration of killed Corynebacterium parvum. Nature 1966;212:853-4.
29. Key ME, Hanna MG I. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. II. Influence of the local inflammatory response on immune reactivity. J Natl Cancer Inst 1981;67:863-9.
30. Eilber FR, Townsend CM, Morton DL. Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Am J Surg 1976;132:476-9.
31. Green AA, Pratt C, Webster RG , Smith K. Immunotherapy of osteosarcoma patients with virus-modified tumor cells. Ann N Y Acad Sci 1976;277:396-411.
32. Sinkovics JG. Immunotherapy with viral oncolysates for sarcoma. JAMA 1977;237:869.
33. Wallack MK, Steplewski Z, Koprowski H, Rosato E, George J, Hulihan B et al. A new approach in specific, active immunotherapy. Cancer 1977;39:560-4.
34. Berthier-Vergnes O, Portoukalian J, Leftheriotis E, Dore JF. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Res 1994;54:2433-9.
35. Jindal S, Young RA. Vaccinia virus infection induces a stress response that leads to association of Hsp70 with viral proteins. J Virol 1992;66:5357-62.
36. Sedger L, Ruby J. Heat shock response to vaccinia virus infection. J Virol 1994;68:4685-9.
37. Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y. Immunotherapy of tumor-bearing mice utilizing virus help. Cancer Immunol Immunother 1988;27:223-7.
38. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181-90.
39. Wallack MK, Scoggin SD, Sivanandham M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mt Sinai J Med 1992;59:227-33.
40. Prabakaran I, Menon C, Xu S, Gomez-Yafal A, Czerniecki BJ, Fraker DL. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells. Ann Surg Oncol 2002;9:411-8.
41. Wallack MK, Sivanandham M. Clinical trials with VMO for melanoma. Ann N Y Acad Sci 1993;690;178-89.
42. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D et al. A phase III randomized, double-blind multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42.
43. Watanabe Y. Fifty years of interference. Nat Immunol 2004;5:1193.
44. Nagano Y, Kojima Y. Immunizing property of vaccinia virus inactivated by ultraviolets rays. C R Seances Soc Biol Fil 1954;148:1700-2.
45. Isaacs A, Lindenmann J. Virus interference. I. the interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
46. Moschos S, Kirkwood JM. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev 2007;18:451-8.
47. Elder DE, Guerry DT, Heiberger RM, LaRossa D, Goldman DI, Clark WH et al. Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg 1983; 71;66-72.
48. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126;438-41.
49. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial, Ann Surg 1993;218:262-67 (discussion 267-9).
50. Bart RS, Porzio NR, Kopf AW, Vilcek JT, Cheng EH, Farcet Y. Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res 1980;40:614-9.
51. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systemic review of systemic adjuvant therapy for patients at high risk for recurrence melanoma. Cancer 2006;106:1431-42.
52. Kalaaji AN. Cytokine therapy in advanced melanoma. J Drugs Dermatol 2007;6:374-7.
53. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
54. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
55. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430-6.
56. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
57. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS. Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for Melanoma. Clin Cancer Res 2004;10:1670-7.
58. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
59. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-8.
60. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose treatment-related morbidity, and histologic findings. J Am Med Assoc 1986;256:3117-24.
61. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
62. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307-19.
63. Eklund JW, Kuzel TM. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treat Res 2005;126:263-87.
64. Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-1-arginine. Cancer J Sci Am 2000;6:S21-S30.
65. Guan H, Nagarkatti PS, Nagarkatti M. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. J Immunol 2007;179:3715-23.
66. Atkins MB. Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am 2000; 6:S8-S10.
67. Dillman RO, Church C, Barth NM, Oldham RK, Wiemann MC. Long-term survival after continuous infusion interleukin-2. Cancer Biother Radiopharm 1997;12:243-8.
68. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003;21:2564-73.
69. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125-33.
70. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
71. Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-88.
72. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75.
73. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
74. Spiess PJ, Yang JC , Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 987;79:1067-75.
75. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21.
76. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988;6:839-53.
77. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, N Engl J Med 1988;319:1676-80.
78. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
79. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25:243-51.
80. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363-73.
81. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005;175:7046-52.
82. Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 2005;65:2001-8.
83. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ, Rosenberg SA, Hodes RJ. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007;30:123-9.
84. Krumme MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
85. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1999;162:5813-20.
86. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-50.
87. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
88. Hodi SF. Cytotoxic-T-Lymphocyte-Associated Antigen-4. Clin Cancer Res 2007;13:5238-42.
89. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA-4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13
90. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13:958-64.
91. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29:455-63.
92. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-62.
93. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
94. Jalili A. Dendritic cells and their role in cancer immunotherapy. Review. Iran J Immunol 2007;5:127-44.
95. Wu L, D'Amico A, Hochrein H, O'Keeffe M, Shortman K, Lucas K. Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 2001;98:3376-82.
96. Mellman I. Antigen processing and presentation by dendritic cells: cell biological mechanisms. Adv Exp Med Biol 2005;560:63-7.
97. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005;23:975-1028.
98. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-23.
99. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000;1:305-10.
100. Megjugorac NJ, Young HA, Amrute SB, Olshalsky SL, Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol 2004;75:504-14.
101. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999;190:1155-64.
102. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol2005;5:296-306.
103. Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000;165:566-72.
104. Gunzer M, Grabbe S. Dendritic cells in cancer immunotherapy. Crit Rev Immunol 2001;21:133-45.
105. Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W et al. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol 1999;163:1289-97.
106. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000;191:1699-708.
107. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000;12:571-5.
108. Moller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 1998;77:1907-16.
109. Escobar A, Lopez M, Serrano A, Ramirez M, Pererz C, Aguirre A et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005;142:555-68.100.
110. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Clin Invest 2005;115:3623-33.
111. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70.
112. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
113. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
114. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-900.
115. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003;98:144-54.
116. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14:709-14.
117. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
118. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-93.
119. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;5:623-35.
120. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067-75.
121. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66.
122. Mitchel MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-69.
123. Wallack MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997;226:198-206.
124. Wallack MK, Michaelides M. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates. Surgery 1984;96:791-800.
125. Wallack MK, McNally KR, Leftheriotis E, Seigler H, Balch C, Wanebo H et al. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer 1986,57:649-55.
126. Wallack MK, Bash JA, Leftheriotis E, Seigler H, Bland K, Wanebo K et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987;122:1460-3.
127. Wallack MK, Meyer M, Bourgoin A, Dore JF, Leftheriotis E, Carcagne J et al. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Response Mod 1983;2:586-96.
128. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a Phase III, Randomized, Double Blinded, Multicenter Vaccinia Melanoma Oncolysate Trial. J Am Coll Surg 1998;187:69-79.
129. Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J Immunol 1996;156:3882-91.
130. Sivanandham M, Scoggin SD, Tanaka N, Wallack MK. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother 1994;38:259-64.
131. Tanaka N, Sivanandham M, Wallack MK. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma. J Immunother Emphasis Tumor Immunol 1994;16:283-93.